Roivant Sciences/$ROIV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Roivant Sciences
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Ticker
$ROIV
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
750
ISIN
BMG762791017
Website
Roivant Sciences Metrics
BasicAdvanced
$7.9B
-
-$0.24
1.23
-
Price and volume
Market cap
$7.9B
Beta
1.23
52-week high
$12.57
52-week low
$8.73
Average daily volume
7.1M
Financial strength
Current ratio
33.465
Quick ratio
32.708
Long term debt to equity
1.741
Total debt to equity
1.931
Profitability
EBITDA (TTM)
-1,099.61
Gross margin (TTM)
-40.06%
Net profit margin (TTM)
-591.96%
Operating margin (TTM)
-3,833.27%
Effective tax rate (TTM)
-7.07%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-11.00%
Return on equity (TTM)
-12.54%
Valuation
Price to revenue (TTM)
290.38
Price to book
1.73
Price to tangible book (TTM)
1.73
Price to free cash flow (TTM)
-9.995
Free cash flow yield (TTM)
-10.00%
Free cash flow per share (TTM)
-116.36%
Growth
Revenue change (TTM)
-11.19%
Earnings per share change (TTM)
-104.53%
3-year revenue growth (CAGR)
-19.30%
3-year earnings per share growth (CAGR)
-42.73%
What the Analysts think about Roivant Sciences
Analyst ratings (Buy, Hold, Sell) for Roivant Sciences stock.
Bulls say / Bears say
Roivant Sciences' subsidiary, Immunovant, reported positive initial Phase I data for its autoimmune antibody, leading to a significant surge in stock prices. (roivant.com)
The company sold its subsidiary, Telavant, to Roche for $7.1 billion upfront, providing substantial capital for future investments. (invezz.com)
Analyst firms such as Goldman Sachs, H.C. Wainwright, and TD Cowen have maintained their 'Buy' ratings on Roivant Sciences, indicating confidence in the company's prospects. (investing.com)
Roivant Sciences reported a higher-than-expected fiscal first-quarter loss, with earnings per share of ($0.38), missing analyst expectations. (roivant.com)
The company's stock reached a new 52-week low, trading as low as $8.73, reflecting potential investor concerns. (techdows.com)
Insider selling activity, including significant stock sales by the COO and CAO, may signal a lack of confidence in the company's short-term prospects. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
Roivant Sciences Financial Performance
Revenues and expenses
Roivant Sciences Earnings Performance
Company profitability
Roivant Sciences News
AllArticlesVideos
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
GlobeNewsWire·4 weeks ago
Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis
GlobeNewsWire·1 month ago
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Roivant Sciences stock?
Roivant Sciences (ROIV) has a market cap of $7.9B as of July 15, 2025.
What is the P/E ratio for Roivant Sciences stock?
The price to earnings (P/E) ratio for Roivant Sciences (ROIV) stock is 0 as of July 15, 2025.
Does Roivant Sciences stock pay dividends?
No, Roivant Sciences (ROIV) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Roivant Sciences dividend payment date?
Roivant Sciences (ROIV) stock does not pay dividends to its shareholders.
What is the beta indicator for Roivant Sciences?
Roivant Sciences (ROIV) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.